COSMIC (Catalogue of Somatic Mutations in Cancer)’s Post

⏰ TOMORROW: Don’t miss your opportunity to engage live with the principal curator behind COSMIC Actionability! Join us tomorrow, March 7 at 11 a.m. EST / 4 p.m. GMT for an exclusive interactive webinar featuring Dr. Steve Jupe, COSMIC Actionability's principal curator and Dr. Kyle Nilson, field software trainer at QIAGEN Digital Insights. In this webinar, you’ll explore a series of use cases demonstrating how #cancer and #biopharma labs like yours can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ➡️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations. ➡️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability. ➡️ Use mutational signatures for potential clinical diagnosis and drug development applications.   Hurry – there’s still time! Register now 👇 Can’t make it at this time? Don’t worry. Register now and we’ll send you the on-demand recording as soon as its available. #drugdevelopment #precisiononcology

🔥 Have burning questions for the curators behind COSMIC Actionability? Here's your chance to get answers!   Join us on March 7 for an exclusive webinar featuring a live Q&A session with Dr. Steve Jupe, COSMIC Actionability's principal curator. Led by Dr. Kyle Nilson, this webinar will explore a series of use cases demonstrating how #cancer and #biopharma labs can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ☑️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations ☑️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability ☑️ Use mutational signatures for potential clinical diagnosis and drug development applications   Don't miss out! Register now ⬇️ #drugdevelopment #precisiononcology

𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗱𝗿𝘂𝗴 𝗰𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 (𝗔𝗗𝗖𝘀) are a highly promising and relatively new class of therapies with a significant clinical impact in cancer treatment. Our latest case study, “𝗔𝗗𝗖 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗶𝘁𝗵 𝗦𝗲𝗹𝘃𝗶𝘁𝗮: 𝗧𝗿𝗮𝘀𝘁𝘂𝘇𝘂𝗺𝗮𝗯 𝗔𝗗𝗖𝘀 𝗶𝗻 𝗛𝗘𝗥𝟮 𝗣𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿” showcases our expertise in characterization of novel ADC binding properties, measuring efficacy in disease-relevant cell lines, and ensuring target specificity through a series of studies. Our findings reveal that treatment with T-Deruxtecan results in increased levels of phosphorylated histone H2AX, indicating DNA damage in a concentration-dependent manner. Discover the full findings from our scientific poster recently showcased at the Drug Discovery 2024 here: https://lnkd.in/eFk-S8Rf Stay updated on more research from Selvita by visiting our website: https://lnkd.in/ebj-PFDG #ADC #DrugDiscovery #CancerResearch #ELRIGDD #DrugDiscovery2024

WHY DANNY eCLINICAL RESEARCH? 📌 70% decrease in NIS start-up cycle 📌 55% reduction in investigator time 📌 5 times faster patient enrolment Curious to explore our success story with ‘Lung Cancer Real-world Evidence Secondary Use of Data: A Non-Interventional Study’? 👇

One of the key topic areas at #WORLDCDX includes CDx in ADCs. #Geneexpression will play a critical role in the development of ADC therapies, the next generation of immunotherapies that hold huge potential for cancer patients. Understanding #transcriptomics data to reveal tumor heterogeneity, immune responses and biomarkers discovery are diverse areas where latest #cfRNA NGS technologies can be utilized to accelerate ADC drug development. Sysmex Inostics’ broad portfolio of comprehensive cfRNA plus cfDNA panels can provide unique solutions to your liquid biopsy needs for ADCs. Come speak with our experts to learn how we can expedite your ADC clinical trials! https://hubs.la/Q02L8G6-0 #cellfreeDNA #ADCs #ADCclinicaltrial

Very interesting webinar on the latest advancements in gastric cancer biomarkers for pathologists!

Watch our panel of experts representing views from across #clinicalresearch, drug commercialization and clinical practice and discuss the state of #breastcancer care today and where it is headed, including: - How organizations across the healthcare industry are tackling complex clinical decision-making - The use of #AI to accelerate breast cancer research and clinical practice - Treatment selection, sequencing and the increasingly critical role of genomic testing ⏯️ On demand now: https://lnkd.in/eAf2_-8z

Our latest paper describes a novel hybrid AI-structure-based approach to identify compounds that target both #G4 DNA structures and the #PARP1 enzyme, offering a promising new strategy for cancer therapy. Key to this breakthrough is our #PyRMD tool, an AI-powered solution that efficiently identified PARP1 inhibitors from vast chemical libraries, streamlining the drug discovery process. We've identified four dual-acting compounds, demonstrating significant antiproliferative activity, especially in cancer cells with DNA repair deficiencies. This breakthrough highlights the power of AI-driven drug discovery, exemplified by PyRMD, in developing innovative multi-target anticancer therapies. A big shout-out to Michele Roggia and Benito Natale for the effort put into this project! #DrugDiscovery #AI #DrugDesign #MedChem #cancerresearch #PyRMD Access the paper: https://lnkd.in/dYXRK532

We're thrilled to share positive data from our Phase 1 trial of INB-100, presented at #EHA2024: Highlights include: • 100% of treated #leukemia patients achieved durable complete remission at 1-year, including those with high-risk #AML and those who failed multiple lines of therapy, including CAR-T. • Data continues to demonstrate long-term in vivo expansion and persistence of allogeneic #GammaDeltaTCells, a first-ever in cellular therapy. • No dose-limiting toxicities, cytokine release syndrome, or neurotoxicity reported. Join our conference call today at 4:15 pm ET and read more here: bit.ly/3KHXoUo Let's continue to push the boundaries of cancer treatment! #CancerZero #GammaDeltaTCells #Biotech #ClinicalTrials #GDTcells #CancerResearch

evitria’s journal club - paper of the week no. 39 The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases @Peyton High et al (July 2024) Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment by targeting the HER family of receptors. This paper highlights the success of HER2-targeted ADCs like trastuzumab emtansine and deruxtecan, and explores new strategies for EGFR and HER3. With 13 FDA-approved ADCs, the potential to overcome drug resistance and reduce systemic toxicity is immense. Exciting advancements in bispecific ADCs and novel payloads are paving the way for more effective therapies. Developing a new ADC? Get in touch with our scientists to learn how we can support you: www.evitria.com/contact #Biotech #ADC #AntibodyTherapeutics